Comparative Pharmacology
Head-to-head clinical analysis: DOXYCHEL versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCHEL versus TETREX.
DOXYCHEL vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily. For severe infections, continue 100 mg every 12 hours.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
12-22 hours (mean ~16 hours); prolonged in severe hepatic impairment (up to 30 hours).
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Renal (20-30%), biliary/fecal (40-60%), with significant enterohepatic circulation; nonrenal elimination accounts for about 70%.
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic